Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amphotericin B nephrotoxicity.

Gilbert Deray1

  • 1Nephrology Department, Pitié-Salpêtrière Hospital, Boulevard de l'Hôpital, Paris 750013, France. gilbert.deray@psl.ap-hop-paris.fr

The Journal of Antimicrobial Chemotherapy
|January 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Microplastics and Nanoplastics on the Kidneys.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

QT-prolonging medications: prevalence of use and associated risks in CKD.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2025
Same author

Drug Exposure in Chronic Kidney Disease: It Is Not Just About the Glomerular Filtration Rate.

Fundamental & clinical pharmacology·2025
Same author

Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.

JACC. Advances·2024
Same author

Risk Profiles and Treatment Patterns in Atrial Fibrillation Patients with Chronic Kidney Disease Receiving or not Receiving Anticoagulation Therapy.

TH open : companion journal to thrombosis and haemostasis·2024
Same author

How the diagnosis and the management of genetic renal phosphate leak impact the life of kidney stone formers?

Urolithiasis·2022
Same journal

β-lactam susceptibility testing of ampicillin-susceptible non-faecalis enterococcal clinical isolates in France.

The Journal of antimicrobial chemotherapy·2026
Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026
Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026
Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Amphotericin B causes significant nephrotoxicity, increasing mortality. Liposomal amphotericin B (AmBisome) demonstrates reduced nephrotoxicity and improved safety compared to conventional amphotericin B and Abelcet.

Area of Science:

  • Nephrology
  • Infectious Diseases
  • Pharmacology

Background:

  • Amphotericin B is a critical antifungal agent but its use is limited by dose-dependent nephrotoxicity.
  • Amphotericin B-induced nephrotoxicity is associated with increased hospital costs, need for hemodialysis, and higher mortality rates.
  • Preventing amphotericin B nephrotoxicity is essential for patient outcomes.

Purpose of the Study:

  • To evaluate the nephrotoxicity of novel amphotericin B formulations.
  • To compare the safety and tolerability of liposomal amphotericin B (AmBisome) and amphotericin B lipid complex (Abelcet).

Main Methods:

  • Review of prospective randomized trials comparing amphotericin B formulations.
  • Analysis of double-blind randomized trials assessing nephrotoxic effects and adverse events.

Related Experiment Videos

  • Comparison of AmBisome and Abelcet in a multicenter double-blind study.

    • Main Results:

    • Liposomal amphotericin B (AmBisome) showed significantly less nephrotoxicity than conventional amphotericin B in multiple studies.
    • AmBisome demonstrated a reduction in azotaemia, even in patients receiving concomitant nephrotoxic agents.
    • A recent study indicated AmBisome has a better safety profile than Abelcet, with fewer adverse events and treatment discontinuations.

    Conclusions:

    • Amphotericin B nephrotoxicity is a frequent and serious complication that increases patient mortality.
    • Early recognition of nephrotoxicity based on tubular abnormalities and elevated creatinine is crucial.
    • The use of AmBisome is recommended for its reduced nephrotoxicity and improved safety profile.